NextCell publishes its Interim Report 1 2022/2023

January 26, 2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First quarter (2022-09-01 until 2022-11-30)

● Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346) TSEK.

● Operating result amounted to -8 918 (-6 472) TSEK.

● Earnings per share* amounted to -0,26 (-0,19) SEK.

● Cash and bank amounted to 88 259 (133 464) TSEK.

● Solidity**amounted to 92,0 (94,1) %.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2022/2023: 34,379,523 (34,379,523)shares. Number of shares in NextCell as of November 30, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the first quarter

● NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.

● In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.

● NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.

● At the end of October, NextCell's CEO, Mathias Svahn, presented an update on the Company's achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.

Significant events after the reporting period

● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.

● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO)

● NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26^th January 2023, 07.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser

‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stem cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to a market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical Covid-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100%of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2020-02-21

The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study

NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to the characterisation, standardisation and control of biological medicines. As part of their activities the NIBSC has been endorsed by the World Health Organization (WHO) to develop and generate a reference for MSCs. The official name of the study/assignment is: “International Collaborative Study to

Read more Read more

2020-02-10

Participates in innovation projects for cell-based products

NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies. The Centre for Advanced Medical Products (CAMP, an initiative of Vinnova) has decided to proceed on the project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies’. The goal of this project is to evaluate the best logistics strategy for cell-based products. This can be done by evaluating

Read more Read more

2020-02-04

NextCell to present its progress at Swiss Nordic Bio 2020

NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company will present data at Swiss Nordic Bio 2020, on February 6 in Zurich. Swiss Nordic Bio is a partnering and investor conference aimed at connecting healthcare innovations, investors and industry. For NextCell this is an opportunity to inform international investors and potential collaborators about

Read more Read more

2020-01-31

Interim Report 1 2019/2020

NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Company’s fiscal year is September 1-August 31. First quarter (2019-09-01 until 2019-11-30) · Operating income amounted to SEK 1 222 087 (73 745). · Operating result amounted to SEK -3 755 926 (-5 440 809). · Earnings per share* amounted to SEK -0,20 (-0,38). · Cash and bank

Read more Read more

2019-12-11

Extended permission from the Medical Products Agency

NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years. The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials. In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory

Read more Read more

2019-12-04

Promising Results from clinical trial with ProTrans stem cells

NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significantly better (P <0.01) as compared to the three patients who received a low-dose of the company's stem cell based drug candidate ProTrans. No serious side effects have been reported. "The results very are promising, even though there are only few patients and this part of the clinical trial was an

Read more Read more

2019-11-22

A part of Vision-driven Health

NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030. Vinnova is investing in establishing five vision-driven innovation environments to meet important health challenges. These include zero vision for malnutrition in the elderly, elimination of cancer as a cause of death and counteracting antibiotic resistance. NextCell is participating in one of the approved five projects: Sweden a leader in advanced therapies in 2030. This project which is

Read more Read more

2019-11-07

Correction: Notice to attend the Annual General Meeting

NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject to the Market Abuse Regulation. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and

Read more Read more

NextCell publishes its Interim Report 1 2022/2023

● Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346) TSEK.

● Operating result amounted to -8 918 (-6 472) TSEK.

● Earnings per share* amounted to -0,26 (-0,19) SEK.

● Cash and bank amounted to 88 259 (133 464) TSEK.

● Solidity**amounted to 92,0 (94,1) %.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2022/2023: 34,379,523 (34,379,523)shares. Number of shares in NextCell as of November 30, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the first quarter

● NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.

● In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.

● NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.

● At the end of October, NextCell's CEO, Mathias Svahn, presented an update on the Company's achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.

Significant events after the reporting period

● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.

● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO)

● NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26th January 2023, 07.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser

‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26^th January 2023, 07.30 CET.